Home World News Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in... World News Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer By Ogkologos - November 15, 2024 730 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPASSION-16 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... October 17, 2019 Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL June 8, 2023 Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... February 8, 2023 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 Load more HOT NEWS New study to detect oesophageal cancer earlier Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... Coming together for Zynlonta Liquid Biopsies on the Horizon for Children with Solid Cancers
